DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,871 filers reported holding DANAHER CORPORATION in Q3 2021. The put-call ratio across all filers is 1.50 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $9,327,352 | +9.9% | 37,595 | +6.3% | 0.94% | +13.1% |
Q2 2023 | $8,486,427 | +18.1% | 35,360 | +24.0% | 0.83% | +10.2% |
Q1 2023 | $7,187,952 | -0.9% | 28,519 | +4.3% | 0.75% | -9.2% |
Q4 2022 | $7,256,602 | +6.2% | 27,340 | +3.4% | 0.83% | -3.9% |
Q3 2022 | $6,832,000 | +3.4% | 26,450 | +1.5% | 0.86% | +9.0% |
Q2 2022 | $6,605,000 | -13.8% | 26,052 | -0.3% | 0.79% | +0.5% |
Q1 2022 | $7,664,000 | -7.7% | 26,129 | +3.5% | 0.79% | -5.0% |
Q4 2021 | $8,307,000 | +10.5% | 25,248 | +2.2% | 0.83% | -0.1% |
Q3 2021 | $7,520,000 | +21.1% | 24,701 | +6.7% | 0.83% | +19.6% |
Q2 2021 | $6,212,000 | +22.0% | 23,148 | +2.3% | 0.69% | +8.1% |
Q1 2021 | $5,091,000 | +1.2% | 22,618 | -0.2% | 0.64% | -7.0% |
Q4 2020 | $5,033,000 | +4.3% | 22,657 | +1.1% | 0.69% | -9.0% |
Q3 2020 | $4,824,000 | +20.4% | 22,405 | -1.1% | 0.76% | +11.3% |
Q2 2020 | $4,005,000 | +33.7% | 22,648 | +4.7% | 0.68% | +7.4% |
Q1 2020 | $2,995,000 | +29.3% | 21,638 | +43.4% | 0.63% | +43.9% |
Q4 2019 | $2,317,000 | -19.3% | 15,094 | -24.1% | 0.44% | -29.0% |
Q3 2019 | $2,871,000 | +4.9% | 19,878 | +3.8% | 0.62% | +0.5% |
Q2 2019 | $2,738,000 | +6.7% | 19,158 | -1.4% | 0.62% | +1.1% |
Q1 2019 | $2,566,000 | +38.0% | 19,436 | +7.7% | 0.61% | +16.9% |
Q4 2018 | $1,860,000 | +98.3% | 18,040 | +109.0% | 0.52% | +126.0% |
Q3 2018 | $938,000 | +149.5% | 8,633 | +126.8% | 0.23% | +133.3% |
Q2 2018 | $376,000 | -85.6% | 3,807 | -85.8% | 0.10% | -86.6% |
Q1 2018 | $2,617,000 | +6.0% | 26,729 | +0.5% | 0.74% | +15.5% |
Q4 2017 | $2,469,000 | -43.8% | 26,599 | -48.4% | 0.64% | +0.6% |
Q3 2017 | $4,390,000 | +102.6% | 51,588 | +100.9% | 0.63% | +0.3% |
Q2 2017 | $2,167,000 | +0.7% | 25,674 | +2.0% | 0.63% | -5.4% |
Q1 2017 | $2,153,000 | +9.9% | 25,172 | 0.0% | 0.67% | +6.2% |
Q4 2016 | $1,959,000 | -0.1% | 25,172 | +0.6% | 0.63% | -9.2% |
Q3 2016 | $1,961,000 | -16.4% | 25,022 | +7.8% | 0.69% | -19.7% |
Q2 2016 | $2,345,000 | +13.8% | 23,222 | +7.0% | 0.86% | +12.4% |
Q1 2016 | $2,060,000 | -0.1% | 21,712 | -2.3% | 0.77% | -6.0% |
Q4 2015 | $2,063,000 | +131.5% | 22,212 | +112.5% | 0.82% | +113.9% |
Q3 2015 | $891,000 | – | 10,452 | – | 0.38% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
Third Point | 2,450,000 | $607,845,000 | 9.22% |
Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |